Axogen, Inc. completed its acquisition of BioCircuit Technologies, Inc., adding NerveTape™, the first FDA-cleared device for sutureless peripheral nerve repair. The company expects BioCircuit to contribute approximately $6 million in revenue during the fourth quarter of 2026 and approximately $34 million in 2027. This contribution is separate from Axogen’s previously issued full-year 2026 guidance, which anticipated at least 24% revenue growth. Axogen maintains its expectation for gross margins of at least 73% and free cash flow positivity for the full year 2026. Axogen operates in the medical device industry, developing and marketing surgical solutions for peripheral nerve regeneration and repair.
